

Evolution of *Klebsiella pneumoniae* Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy

Gabriele Arcari, Federico Cecilia, Alessandra Oliva, Riccardo Polani, Giammarco Raponi, Federica Sacco, Alice De Francesco, Francesco Pugliese, Alessandra Carattoli

In February 2022, a critically ill patient colonized with a carbapenem-resistant *K. pneumoniae* producing KPC-3 and VIM-1 carbapenemases was hospitalized for SARS-CoV-2 in the intensive care unit of Policlinico Umberto I hospital in Rome, Italy. During 95 days of hospitalization, ceftazidime/avibactam, meropenem/vaborbactam, and cefiderocol were administered consecutively to treat 3 respiratory tract infections sustained by different bacterial agents. Those therapies altered the resistome of *K. pneumoniae* sequence type 512 colonizing or infecting the patient during the hospitalization period. In vivo evolution of the *K. pneumoniae* sequence type 512 resistome occurred through plasmid loss, outer membrane porin alteration, and a nonsense mutation in the *cirA* siderophore receptor gene, resulting in high levels of cefiderocol resistance. Cross-selection can occur between *K. pneumoniae* and treatments prescribed for other infective agents. *K. pneumoniae* can stably colonize a patient, and antimicrobial-selective pressure can promote progressive *K. pneumoniae* resistome evolution, indicating a substantial public health threat.

The number of deaths caused by antimicrobial resistance was estimated at 1.27 million worldwide in 2019 (1), mainly attributed to 6 bacterial species: *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Streptococcus pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*. To reinforce the antimicrobial

drug pipeline, the European Union's European Medicines Agency authorized the clinical use of ceftazidime/avibactam (CZA) in 2016, meropenem/vaborbactam (MVB) in 2018, and cefiderocol (FDC) in 2020. Although those drugs all belong to the β -lactams class, substantial differences in mechanisms of action and antimicrobial spectra exist among them. CZA is a third-generation cephalosporin (ceftazidime) combined with a diazabicyclooctane β -lactamase inhibitor (avibactam). Avibactam prevents class A (including *K. pneumoniae* carbapenemase [KPC]), class C, and some class D β -lactamases from hydrolyzing ceftazidime, restoring ceftazidime activity in KPC- and oxacillinase-48-producing Enterobacterales but not in metallo- β -lactamase producers (2). MVB is a carbapenem (meropenem) combined with a boronate β -lactamase inhibitor (vaborbactam); vaborbactam inhibits class A but not class D or B carbapenemases (3). FDC is a siderophore cephalosporin that has a catechol moiety on the C-3 side chain (4), which can form a chelating complex with ferric iron; thus, FDC is subject to active transport through the iron transport system, including TonB-dependent receptors (5). In addition, FDC is highly stable against β -lactamase activity (4,5).

In the past decade, Italy has seen a large increase in cases of carbapenem-resistant *K. pneumoniae* (1), mainly from 3 major KPC-producing (6) sequence types (STs): 101, 307, and 512 (7). In settings highly endemic for KPC-producing Enterobacterales, the selection of CZA-resistant, KPC-producing variants is of great concern (8,9). FDC resistance is not a 1-dimensional phenomenon (10); mutations in siderophore receptors (11), as well as in variants of β -lactamases KPC-2, CMY-2, CTX-M-15, and NDM-1, can con-

Author affiliations: Sapienza University of Rome, Rome, Italy (G. Arcari, F. Cecilia, A. Oliva, R. Polani, G. Raponi, A. De Francesco, F. Pugliese, A. Carattoli); Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome (A. Oliva, G. Raponi, F. Sacco, F. Pugliese)

DOI: <https://doi.org/10.3201/eid2911.230921>

fer FDC resistance (12). Nonetheless, *cirA* disruption substantially hinders bacterial fitness (13), and β -lactamase evolution contributing to FDC resistance typically comes at the price of functional trade-offs against other β -lactams (12). Under FDC treatment, in vivo resistance has been reported sporadically in *Enterobacter cloacae* (14) and *Escherichia coli* (15).

We describe a patient in Rome, Italy, who was colonized by carbapenem-resistant *K. pneumoniae* ST512. We integrated whole-genome sequencing, clinical, and microbiologic data to reconstruct the evolution of *K. pneumoniae* antimicrobial resistance in this patient after treatments for respiratory tract infections caused by different bacteria.

Methods

Case Report

In February 2022, a 62-year-old patient who was positive for SARS-CoV-2 was transferred from a long-term care facility to Policlinico Umberto I (PUI) in Rome. The patient was hospitalized for 95 days initially in the COVID-19 intensive care unit (ICU) and then in the general ICU until death, which was caused by gastrointestinal bleeding. The patient's medical history was notable for bipolar disorder, obesity, inflammatory bowel disease, type 2 diabetes, respiratory failure, chronic kidney failure, and heart failure. Six months before transfer to PUI, the patient had a percutaneous endoscopic gastrostomy performed because of severe gastrointestinal bleeding caused by underlying inflammatory bowel disease. During the patient's hospitalization at PUI, we isolated a total of 5 different *K. pneumoniae* strains from patient rectal swab samples and respiratory tract specimens.

Isolation of *K. pneumoniae* Strains and Susceptibility Testing

We identified the 5 *K. pneumoniae* strains by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonik GmbH, <https://www.bruker.com>). We identified carbapenamase genes by PCR using the GeneXpert system (Cepheid, <https://www.cepheid.com>) and used the lateral flow immunochromatography systems (NG-Test CARBA 5; Hardy Diagnostics, <https://www.hardydiagnostics.com>). We tested antimicrobial drug susceptibility by using the MicroScan WalkAway system (Beckman Coulter, Inc., <https://beckman.com>). We used gradient strips (Liofilchem, <https://www.liofilchem.com>) to test MVB and CZA MICs and the Compact Antimicrobial Susceptibility Panel (ComASP; Liofilchem) to test FDC MICs.

Whole-Genome Sequencing and Assembly

We performed whole-genome sequencing for each isolate. We purified genomic DNA by using the Isolate II Genomic DNA Kit (Bioline, <https://www.bioline.com>). We sent DNA to an external service to perform short-read Illumina sequencing (Illumina Inc., <https://www.illumina.com>). We obtained long reads by using the MinION Mk1C sequencing platform (Oxford Nanopore Technologies, <https://nanoporetech.com>). We extracted DNA for long reads by using the Wizard HMW DNA Extraction Kit (Promega, <https://www.promega.com>) and prepared libraries by using the Rapid Barcoding Kit 96; we sequenced libraries on R9.4.1 flow cells (Oxford Nanopore Technologies). We performed long-read assemblies by using Flye (16) with standard parameters. We integrated Illumina reads and Oxford Nanopore Technologies assemblies by using the Unicycler tool (17) in normal bridging mode and refined results by using the Bandage tool (18).

Genomic and Phylogenetic Analyses

We analyzed single-nucleotide polymorphisms (SNPs) among the 5 sequenced genomes in this study by using the Snippy tool (<https://github.com/tseemann/snippy>). We annotated the 5 genomes by using Rapid Annotation using Subsystem Technology and compared by using SEED software (19).

We used Prokka software (20) to annotate 133 genomes belonging to ST512: 5 sequences from this study, 12 from a previous study performed at PUI (8), and 116 downloaded from the Pasteur Institute BIGSdb database (<https://bigsdb.pasteur.fr/klebsiella>). We analyzed the resulting general feature formats by using Roary software (21) to build a core genome alignment and generated a consensus phylogenetic tree by using 1,000 ultrafast bootstraps (22) in IQ-TREE 2 (23) and the transversion model plus base frequency plus proportion of invariable sites nucleotide substitution model (24). We visualized tree and metadata by using Microreact (25) and adjusted those data by using open source InkScape software (<https://www.inkscape.org>). We assessed all genomes for replicons by using PlasmidFinder (26), for capsular polysaccharide and lipopolysaccharide loci by using Kaptive (27), and for virulence and resistance gene content by using Kleborate (28) software.

Cloning *bla*_{KPC-154} in pCR-Blunt II TOPO Vector

We cloned the novel β -lactamase *bla*_{KPC-154} allele from isolate 6099 into pCR-Blunt II TOPO-NeoR Vector and transformed TOP10 *E. coli* cells (both

Thermo Fisher Scientific, <https://www.thermo-fisher.com>); we confirmed correctness of the cloned insert by Sanger sequencing. We tested the KPC-154 TOP10 *E. coli* clone for antimicrobial drug susceptibility by using the MicroScan system and measured CZA MICs by gradient tests (Liofilchem) as previously described.

OmpK36 Variant Modeling

We predicted structures of the outer membrane porin (Omp) K36 from isolate 0296 in silico by using AlphaFold2 on the European Galaxy server (<https://usegalaxy.eu>) and analyzed those structures by using UCSF ChimeraX (29) for both the cartoon (ribbon) and surface images. We compared the structures with chain B in the crystal structure of OmpK36 from a *K. pneumoniae* ST258 clinical isolate that has a GD amino acid insertion (30). We used the Orientations of Proteins in Membranes database (31) to obtain spatial arrangements of the protein structures in lipid bilayers.

Data Availability

We submitted the sequences of the strains analyzed in this study to GenBank. Whole-genome sequences are under Bioproject no. PRJNA992043 and complete plasmid sequences under accession nos. OQ096263 (pK-pQIL-6099), OQ282880 (pIncA-6379), and OQ282881 (pIncA-0296).

Ethics Approval

According to the hospital's routine practice, the patient or his relatives gave informed consent to share data for research purposes during hospital admission. The study protocol was approved by the Ethics Committee of Azienda Ospedaliero-Universitaria Policlinico Umberto I (approval no. 109/2020).

Results

K. pneumoniae Strain Descriptions

On the first day of the patient's hospitalization at PUI, surveillance rectal swab samples tested positive for *K. pneumoniae* (strain 6379) that produced both KPC and Verona integron-encoded metallo- β -lactamase (VIM) (Figure 1). The patient had been treated with CZA at the long-term care facility for a previous carbapenem-resistant *K. pneumoniae* bloodstream infection; treatment was discontinued upon admission to PUI.

After 17 days of hospitalization, a respiratory tract infection caused by *Providencia stuartii* (>100,000 CFU/mL in bronchoalveolar lavage fluid) developed in the patient, accompanied by pleural effusion, which we treated with CZA. After 1 week of treatment, we

isolated 2 CZA-resistant, meropenem-susceptible *K. pneumoniae* strains from patient rectal swab samples but not respiratory tract specimens; both strains produced KPC but not VIM and had dimorphic colony phenotypes: white (strain 1186W) and transparent (strain 1186T). Because of potential pleural infection, we maintained CZA therapy for \approx 40 days, resulting in complete eradication of *P. stuartii* from the respiratory tract.

On day 56, the patient was SARS-CoV-2 negative and was transferred to the general ICU at PUI. Respiratory tract samples were negative for *P. stuartii* but positive (>1,000 CFU/mL lavage fluid) for CZA-resistant *K. pneumoniae* (strain 6099) that produced KPC. CZA therapy was stopped, and MVB treatment was begun and continued until day 75. On day 75, respiratory tract samples tested negative for *K. pneumoniae* but positive for carbapenem-resistant *A. baumannii* (1,000 CFU/mL lavage fluid). Because of subsequent worsening respiratory conditions and chest imaging suggestive of new onset pneumonia, we replaced MVB therapy with FDC therapy (day 79) to treat *A. baumannii* pulmonary infection. On day 88, during FDC treatment, respiratory tract samples tested positive for both *A. baumannii* and *K. pneumoniae* (strain 0296) (1,000 CFU/mL lavage fluid each); strain 0296 was positive for KPC and VIM carbapenemases.

Phylogeny, Antimicrobial Resistance, and General Features of ST512

We assigned the 5 *K. pneumoniae* isolates from the patient (6379, 1186W, and 1186T from rectal swab samples, 6099 and 0296 from respiratory tract samples) to ST512 by using in silico multilocus sequence typing of whole-genome sequences. We aligned the complete genomes of those strains against 116 ST512 genomes retrieved from the Pasteur Institute *K. pneumoniae* BIGSdb database (December 7, 2022) and 12 ST512 genomes previously identified at PUI (8,32). Phylogeny of 4,654 core genes showed how isolates from the patient clustered together in the same clade with ST512 strains isolated at PUI during 2018–2020 (Figure 2) and were separated by 0–11 SNPs (Appendix 1 Table 1, <https://wwwnc.cdc.gov/EID/article/29/11/23-0921-App1.xlsx>).

All ST512 isolates are defined by conserved features: the *wzi* allele 154 (assigned to the KL107 capsule), typical of the main clade II of clonal group 258 (33); O1/O2v2 O locus, serotype O2afg; 35Q mutation in the chromosome-encoded SHV-11 β -lactamase (28); premature stop at codon 89 in the OmpK35 protein, in most isolates coupled with a GD amino acid insertion in the OmpK36 eyelet (34); and chromosome




Figure 1. Timeline of colonization and infection of 1 patient by *Klebsiella pneumoniae* clones in study of genotypic evolution of *K. pneumoniae* sequence type 512 during ceftazidime/avibactam, meropenem/vaborbactam, and cefiderocol treatment, Italy. A) Schematic diagram of carbapenemase genes and plasmid content for *K. pneumoniae* strains 6379, 1186, 6099, and 0296; strain 1186 comprised 2 phenotypes: W and T colonies. Isolate collection day is indicated during 95 hospitalization days in either the COVID-19 (purple scale) or general (yellow scale) intensive care unit. Asterisk indicates the premature stop codon at position 133 (E133) in the catechol iron outer membrane transporter CirA. B) Timeline of colonization and infection by *K. pneumoniae*, *Providencia stuartii*, and *Acinetobacter baumannii* as well as β-lactam therapies. C) Phylogenetic analysis used to compare the 5 *K. pneumoniae* strains isolated from the same patient. Core genome alignments were conducted for 5,215 core genes. KPC variants KPC-154, KPC-3, and KPC-31 are shown according to each strain; the *bla*_{VIM-1} gene was present in strains 0296 and 6379. Nonsense mutation in *cirA* was found in strain 0296, producing a premature stop codon (E133), indicated by an asterisk, in the protein. FDC MICs (mg/L) for each strain are shown. Scale bar indicates number of single-nucleotide polymorphisms in the core genome. FDC, cefiderocol; ICU, intensive care unit; KPC, *K. pneumoniae* carbapenemase; MDR, multidrug resistant; OmpK36, outer membrane porin K36; T, transparent; VIM, Verona integron-encoded metallo-β-lactamase; W, white; WGS, whole-genome sequencing.

mutations in the *gyrA* (S83I) and *parC* (S80I) genes potentially conferring quinolone resistance (35). The 5 isolates in this study had additional common features diverging from the average ST512 strain: a SNP in the *mgrB* gene, which stops translation at aa 29 of the MgrB regulator protein, conferring resistance to colistin (36); a SNP in the *uhpB* gene, which stops translation at aa 206 of the UhpB protein (37), conferring resistance to fosfomycin; and the presence of the locus encoding yersiniabactin siderophore, designated as YbST157 (38). The yersiniabactin siderophore is not common in ST512 isolates because this locus could only be found in 31/133 (23%) ST512 genomes from the BIGSdb collection.

The 5 *K. pneumoniae* strains carried multiple acquired resistance genes (Appendix 2 Table 1,

<https://wwwnc.cdc.gov/EID/article/29/11/23-0921-App2.pdf>). Plasmid content of the 5 ST512 strains from the patient was not homogeneous: strains 6379 (first strain isolated) and 0296 (last strain isolated) both carried the pKpQIL plasmid containing the *bla*_{KPC-3} gene and IncA plasmid carrying the *bla*_{VIM-1} gene (Figures 1, 2). Strains 1186W, 1186T, and 6099 lacked the IncA-*bla*_{VIM-1} plasmid.

KPC Variants Conferring Resistance to Ceftazidime/Avibactam

On day 24, *K. pneumoniae* strains 1186W and 1186T colonized the patient (isolated from rectal swab samples). Those strains were negative for VIM-1 (loss of plasmid pIncA-*bla*_{VIM-1}) but reached high levels of CZA resistance through the production




Figure 2. Phylogenetic analysis and genetic features of *Klebsiella pneumoniae* ST512 in study of the strain’s genotypic evolution during ceftazidime/avibactam, meropenem/vaborbactam, and cefiderocol treatment, Italy. Phylogenetic tree was constructed from 4,654 core gene alignments from a total of 133 *K. pneumoniae* ST512 genome sequences: 5 genomes sequenced in this study (pink shading), 12 genomes from the same hospital (pale blue shading), and 116 genomes downloaded from the Pasteur Institute BIGSdb database (<https://bigsd.b.pasteur.fr/klebsiella>). Colors indicate resistance and acquired-resistance genes (or corresponding proteins) associated with carbapenemases, yersiniabactin, and chromosomal mutations within the different strains. The same color in the legend on the left indicates the expected resistance phenotype. Asterisk after CirA E133 indicates this mutation produced a premature stop codon. Scale bar indicates number of single-nucleotide polymorphisms in the core genome. Del, deletion; KPC, *K. pneumoniae* carbapenemase; PUI, Policlinico Umberto I; ST, sequence type; VIM, Verona integron-encoded metallo-β-lactamase.

of KPC-31. The *bla*_{KPC-31} gene replaced *bla*_{KPC-3} on an otherwise indistinguishable pKpQIL plasmid; the plasmid was integrated in the chromosome only in strain 1186W. The KPC-31 variant is characterized by a D179Y substitution in the Ω loop, previously shown to confer CZA resistance but restores carbapenem susceptibility (39).

On day 51, CZA-resistant *K. pneumoniae* strain 6099 caused a respiratory tract infection in the patient (Table). This strain hosted a pKpQIL plasmid encoding a novel KPC variant that was assigned by GenBank as KPC-154 (accession no. OQ096263) and was negative for the VIM-encoding IncA plasmid. Compared with KPC-3, KPC-154 has an RAPNKD-

DKYS amino acid duplication in position 263–273, corresponding to the 270 loop (40), but no differences are present in the Ω loop. When compared with an isogenic KPC-31-carrying strain, the strain carrying KPC-154 had higher MICs for several β-lactams (Appendix 2 Table 2).

Cefiderocol Resistance in ST512 Isolates Co-Producing KPC and VIM

K. pneumoniae strain 0296 (pulmonary infectious agent, isolated on day 88) was genotypically related to strain 6379 (colonizer, isolated on day 1). Both strains had similar plasmid content, including pKpQIL carrying *bla*_{KPC-3} and pIncA carrying

Table. MICs of antimicrobial drugs for *Klebsiella pneumoniae* sequence type 512 strains analyzed in study of genotypic evolution of such strains during ceftazidime/avibactam, meropenem/vaborbactam, and cefiderocol treatment, Italy*

Strain	AZT	CZA†	FDC‡	MEM	MVB†	IMI	COL	FOS	AMK	GTM	CIP	SXT	TGC
6379	>4	>256	8	32	1.5	>8	>4	>64	16	≤2	>1	>4/76	2
1186W	>4	32	2	2	0.25	≤1	>4	>64	>16	≤2	>1	≤2/38	≤1
1186T	>4	32	2	4	0.25	≤1	>4	>64	>16	≤2	>1	≤2/38	≤1
6099	>4	16	1	16	0.5	>8	>4	>64	≤8	≤2	>1	≤2/38	≤1
0296	>4	>256	32	32	0.047	>8	>4	>64	≤8	≤2	>1	>4/76	≤1
EUCAST breakpoint	4	8	2	8	8	4	2	32	8	2	0.5	4	ND

*MICs are mg/L. Bold indicates resistance to antimicrobial drugs according to EUCAST breakpoints. AMK, amikacin; AZT, aztreonam; CIP, ciprofloxacin; COL, colistin; CZA, ceftazidime/avibactam; EUCAST, European Committee on Antimicrobial Susceptibility Testing (<https://www.eucast.org>); FDC, cefiderocol; FOS, fosfomycin; GTM, gentamicin; IMI, imipenem; MEM, meropenem; MVB, meropenem/vaborbactam; ND, not done; SXT, trimethoprim/sulfamethoxazole; TGC, tigecycline.

†Tested by using the gradient strip method (Liofilchem, <https://www.liofilchem.com>).

‡Tested by using the Compact Antimicrobial Susceptibility Panel broth microdilution method (Liofilchem).

*bla*_{VIM-1} (Figures 1, 2). However, isolate 0296 carried a pKpQIL-pKPN fused plasmid carrying *catA1*, *dfrA12*, *aadA2*, *aph(3')-Ia* genes, 2 copies of *mph(A)*, *sul1*, and Δ *qacE* genes (Appendix 2 Table 1), and the previously described putative gene involved in iron acquisition (*fec*) (41), all of which were not present in plasmid pKPN from isolate 6379. Within the core genome, strain 0296 had 7 SNPs and 3 deletions when compared with strain 6379 (Appendix 1 Table 2); 1 SNP created a premature stop codon at position 133 in the iron transporter protein CirA (Table 1; Figure 1) (42). Strain 0296 showed 4-fold higher FDC MIC than strain 6379 (6379 FDC MIC = 8 mg/L; 0296 FDC MIC = 32 mg/L). Moreover, in strain 0296, a conservative in-frame deletion resulted in a novel mutation within OmpK36; the deletion was 26 aa (residues Thr263 to Tyr289) according to the reference OmpK36 crystal structure in the Protein Data Bank (no. 6RCP; <https://www.rcsb.org>) (30). The in silico predicted 3-dimensional structure of the mutated OmpK36 porin showed a deep lateral cave, probably favoring MVB permeability from the extracellular site into the periplasmic space (Figure 3). Strain 0296 carrying the mutated OmpK36 protein showed a 5-fold reduction in MVB MICs compared with strain 6379 (6379 MVB MIC = 1.5 mg/L; 0296 MVB MIC = 0.047 mg/L).

Discussion

We report the in vivo evolution of antimicrobial resistance in *K. pneumoniae* high-risk ST512 strains (43) that colonized or infected a critical patient during a 95-day hospitalization. From both phenotypic and genotypic perspectives, each *K. pneumoniae* isolate had univocal characteristics. The rare mutation in the UhpABC signaling pathway conferred fosfomycin resistance by altering expression of the hexose phosphate transporter (44,45). Mutations in the *mgrB* gene, identified in the 5 strains isolated in this study, 8 strains isolated during 2018–2020 at the PUI (8), and globally in 37/133 (27.8%) whole-genome sequences from the Pasteur Institute ST512 collection, conferred colistin resistance. Moreover, the 5 strains from this study carried the yersiniabactin locus, a virulence factor rarely reported in ST512 clones. The yersiniabactin locus was identified in a *K. pneumoniae* ST512 cluster sampled in the framework of the SPARK project from a single city located in northern Italy during 2017–2018 (46). All of those factors support the hypothesis that a single *K. pneumoniae* clone was obtained from the patient first from rectal swab samples and subsequently from the respiratory tract, rather than antimicrobial drug treatment selecting 5 distinct strains.




Figure 3. In silico 3-dimensional structure predictions for mutated OmpK36 porin in *Klebsiella pneumoniae* sequence type 512 strain 0296 in study of *K. pneumoniae* genotypic evolution during ceftazidime/avibactam, meropenem/vaborbactam, and cefiderocol treatment, Italy. The outer membrane porin OmpK36 from strain 0296 (blue) containing a 26 aa deletion from residue Thr263 through residue Tyr289 was modeled and compared with the model of reference OmpK36 chain B crystal structure from the Protein Data Bank (no. 6RCP; <https://www.rcsb.org>) (30). Both ribbon cartoon (top) and surface (bottom) models are shown. Structures for strain 0296 were obtained by using AlphaFold2 on the European Galaxy server (<https://usegalaxy.eu>). Spatial arrangements of the porins in lipid bilayers were visualized by using the positioning of proteins in membranes web server in the Orientations of Proteins in Membranes database (31).

The development of β -lactam resistance in *K. pneumoniae* ST512 strains is a critical concern. At the time of transfer to PUI from a long-term care facility, the patient was colonized by a carbapenem-resistant *K. pneumoniae* strain that produced KPC-3 and VIM-1. Although KPC-3 production by *K. pneumoniae* is a persistent phenomenon in Italy (6), the spread of VIM-producing *K. pneumoniae* is less common. However, we previously described an Enterobacterales infection outbreak at PUI caused by IncA plasmids encoding VIM (47). Therefore, we hypothesize that an elusive and untraced spread of VIM-producing Enterobacterales might exist in hospitals and long-term care facilities in Rome.

During the first 3 weeks of hospitalization, the patient was not treated with β -lactams. We introduced CZA therapy to treat a respiratory tract infection sustained by *P. stuartii*, a pathogen more frequently associated with urinary tract infections (48) but also related to respiratory tract infections (49,50). After 3 days of CZA treatment, a KPC-31-producing, CZA-resistant *K. pneumoniae* strain colonized in the patient and then evolved to an infection by a KPC-154-producing CZA-resistant variant. The KPC-154 clone had a wild type Ω loop but a 13 aa insertion in the 270 loop of the enzyme, a feature previously described in other KPC variants (8).

We used MVB to treat the KPC-154-producing *K. pneumoniae* infection, which eradicated the *K. pneumoniae* strain from respiratory tract samples. However, a respiratory tract infection sustained by *A. baumannii* developed in the patient, who we then treated with FDC. Under FDC treatment, the respiratory tract sample tested positive for *K. pneumoniae* ST512 that was identical to the first colonizing strain, producing both KPC-3 and VIM-1 carbapenemases. This result suggests that a mixed population of KPC/VIM-positive and KPC-positive/VIM-negative *K. pneumoniae* was present in the patient during the entire hospitalization period. VIM-1-negative strains prevailed under CZA treatment, whereas MVB and FDC treatments selected the expansion of VIM-1-producing strains, which likely remained in a hidden reservoir within the patient.

The reemerged KPC/VIM producer had a high MIC for FDC because of the loss-of-function mutation in the CirA siderophore receptor. CirA mutations have previously been associated with FDC resistance in an in vitro model of New Delhi metallo- β -lactamase-producing *K. pneumoniae* (11) and in vivo for *E. cloacae* (14) and *E. coli* (15). However, the KPC/VIM-producing *K. pneumoniae* strain showed increased susceptibility to MVB, probably associated

with a novel OmpK36 structure showing a large protein deletion; the 3-dimensional porin structure predicted a large lateral cave that might increase permeability of MVB. Nonetheless, the mutant OmpK36 could also be interpreted as a compensatory mutation that promotes survival of the CirA-defective strain.

We used last resort β -lactam-based antimicrobial drugs (CZA, MVB, and FDC) to treat the patient but only used MVB to treat the respiratory tract infection sustained by the CZA-resistant ST512 *K. pneumoniae*; other antimicrobial drugs were administered to treat infections caused by *P. stuartii* or *A. baumannii*. This case report serves as a warning that cross-selection can occur between *K. pneumoniae* and treatments prescribed against other infective agents and that *K. pneumoniae* can stably colonize a patient for a long period, promoting progressive evolution of the resistome under increasing selective pressure.

This research was supported by European Union funding (to A.C., A.O., and G.A.) from the NextGeneration EU-MUR PNRR Extended Partnership Initiative on Emerging Infectious Diseases (project no. PE00000007, PE13 INF-ACT, Spoke 3).

About the Author

Dr. Arcari is a researcher at Sapienza University of Rome, Italy. His main interests focus on antimicrobial resistance mechanisms and their dissemination in bacterial pathogens.

References

- Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al.; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399:629–55. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. *Drugs*. 2018;78:675–92. <https://doi.org/10.1007/s40265-018-0902-x>
- Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β -lactam- β -lactamase inhibitor combinations. *Clin Microbiol Rev*. 2020;34:e00115-20. <https://doi.org/10.1128/CMR.00115-20>
- El-Lababidi RM, Rizk JG. Cefiderocol: a siderophore cephalosporin. *Ann Pharmacother*. 2020;54:1215–31. <https://doi.org/10.1177/1060028020929988>
- Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2016;60:7396–401. <https://doi.org/10.1128/AAC.01405-16>
- David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al.; EuSCAPE Working Group; ESGEM Study

- Group. Epidemic of carbapenem-resistant *Klebsiella pneumoniae* in Europe is driven by nosocomial spread. *Nat Microbiol*. 2019;4:1919–29. <https://doi.org/10.1038/s41564-019-0492-8>
7. Di Pilato V, Errico G, Monaco M, Giani T, Del Grosso M, Antonelli A, et al.; AR-ISS Laboratory Study Group on carbapenemase-producing *Klebsiella pneumoniae*. The changing epidemiology of carbapenemase-producing *Klebsiella pneumoniae* in Italy: toward polyclonal evolution with emergence of high-risk lineages. *J Antimicrob Chemother*. 2021;76:355–61. <https://doi.org/10.1093/jac/dkaa431>
 8. Carattoli A, Arcari G, Bibbolino G, Sacco F, Tomolillo D, Di Lella FM, et al. Evolutionary trajectories toward ceftazidime-avibactam resistance in *Klebsiella pneumoniae* clinical isolates. *Antimicrob Agents Chemother*. 2021;65:e0057421. <https://doi.org/10.1128/AAC.00574-21>
 9. Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, et al. *Klebsiella pneumoniae* carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview. *Antimicrob Agents Chemother*. 2022;66:e0044722. <https://doi.org/10.1128/aac.00447-22>
 10. Karakonstantis S, Rousalis M, Kritsotakis EI. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. *Antibiotics (Basel)*. 2022;11:723. <https://doi.org/10.3390/antibiotics11060723>
 11. McElheny CL, Fowler EL, Iovleva A, Shields RK, Doi Y. In vitro evolution of cefiderocol resistance in an NDM-producing *Klebsiella pneumoniae* due to functional loss of CirA. *Microbiol Spectr*. 2021;9:e0177921. <https://doi.org/10.1128/Spectrum.01779-21>
 12. Fröhlich C, Sorum V, Tokuriki N, Johnsen PJ, Samuelsen Ø. Evolution of β -lactamase-mediated cefiderocol resistance. *J Antimicrob Chemother*. 2022;77:2429–36. <https://doi.org/10.1093/jac/dkac221>
 13. Lan P, Lu Y, Jiang Y, Wu X, Yu Y, Zhou J. Catecholase siderophore receptor CirA impacts cefiderocol susceptibility in *Klebsiella pneumoniae*. *Int J Antimicrob Agents*. 2022;60:106646. <https://doi.org/10.1016/j.ijantimicag.2022.106646>
 14. Klein S, Boutin S, Kocer K, Fiedler MO, Störzinger D, Weigand MA, et al. Rapid development of cefiderocol resistance in carbapenem-resistant *Enterobacter cloacae* during therapy is associated with heterogeneous mutations in the catecholase siderophore receptor cirA. *Clin Infect Dis*. 2022;74:905–8. <https://doi.org/10.1093/cid/ciab511>
 15. Jousset AB, Poignon C, Yilmaz S, Bleibtreu A, Emeraud C, Girlich D, et al. Rapid selection of a cefiderocol-resistant *Escherichia coli* producing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor. *J Antimicrob Chemother*. 2023;78:1125–7. <https://doi.org/10.1093/jac/dkad004>
 16. Freire B, Ladra S, Parama JR. Memory-efficient assembly using Flye. *IEEE/ACM Trans Comput Biol Bioinform*. 2022;19:3564–77. <https://doi.org/10.1109/TCBB.2021.3108843>
 17. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. *PLOS Comput Biol*. 2017;13:e1005595. <https://doi.org/10.1371/journal.pcbi.1005595>
 18. Wick RR, Schultz MB, Zobel J, Holt KE. Bandage: interactive visualization of de novo genome assemblies. *Bioinformatics*. 2015;31:3350–2. <https://doi.org/10.1093/bioinformatics/btv383>
 19. Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, et al. The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST). *Nucleic Acids Res*. 2014;42:D206–14. <https://doi.org/10.1093/nar/gkt1226>
 20. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. 2014;30:2068–9. <https://doi.org/10.1093/bioinformatics/btu153>
 21. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics*. 2015;31:3691–3. <https://doi.org/10.1093/bioinformatics/btv421>
 22. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: improving the ultrafast bootstrap approximation. *Mol Biol Evol*. 2018;35:518–22. <https://doi.org/10.1093/molbev/msx281>
 23. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. *Mol Biol Evol*. 2020;37:1530–4. <https://doi.org/10.1093/molbev/msaa015>
 24. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. *Nat Methods*. 2017;14:587–9. <https://doi.org/10.1038/nmeth.4285>
 25. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, et al. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. *Microb Genom*. 2016;2:e000093. <https://doi.org/10.1099/mgen.0.000093>
 26. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother*. 2014;58:3895–903. <https://doi.org/10.1128/AAC.02412-14>
 27. Lam MMC, Wick RR, Judd LM, Holt KE, Wyres KL. Kaptive 2.0: updated capsule and lipopolysaccharide locus typing for the *Klebsiella pneumoniae* species complex. *Microb Genom*. 2022;8:000800. <https://doi.org/10.1099/mgen.0.000800>
 28. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic surveillance framework and genotyping tool for *Klebsiella pneumoniae* and its related species complex. *Nat Commun*. 2021;12:4188. <https://doi.org/10.1038/s41467-021-24448-3>
 29. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. *Protein Sci*. 2021;30:70–82. <https://doi.org/10.1002/pro.3943>
 30. Wong JLC, Romano M, Kerry LE, Kwong HS, Low WW, Brett SJ, et al. OmpK36-mediated carbapenem resistance attenuates ST258 *Klebsiella pneumoniae* in vivo. *Nat Commun*. 2019;10:3957. <https://doi.org/10.1038/s41467-019-11756-y>
 31. Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI. OPM: orientations of proteins in membranes database. *Bioinformatics*. 2006;22:623–5. <https://doi.org/10.1093/bioinformatics/btk023>
 32. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. *Wellcome Open Res*. 2018;3:124. <https://doi.org/10.12688/wellcomeopenres.14826.1>
 33. Deleo FR, Chen L, Porcella SF, Martens CA, Kobayashi SD, Porter AR, et al. Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 *Klebsiella pneumoniae*. *Proc Natl Acad Sci USA*. 2014;111:4988–93. <https://doi.org/10.1073/pnas.1321364111>
 34. García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, et al. An ertapenem-

- resistant extended-spectrum- β -lactamase-producing *Klebsiella pneumoniae* clone carries a novel OmpK36 porin variant. *Antimicrob Agents Chemother*. 2010;54:4178–84. <https://doi.org/10.1128/AAC.01301-09>
35. Deguchi T, Fukuoka A, Yasuda M, Nakano M, Ozeki S, Kanematsu E, et al. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 1997;41:699–701. <https://doi.org/10.1128/AAC.41.3.699>
 36. Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, et al.; COLGRIT Study Group. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing *Klebsiella pneumoniae* of clinical origin. *Antimicrob Agents Chemother*. 2014;58:5696–703. <https://doi.org/10.1128/AAC.03110-14>
 37. Verhamme DT, Arents JC, Postma PW, Crielaard W, Hellingwerf KJ. Glucose-6-phosphate-dependent phosphoryl flow through the Uhp two-component regulatory system. *Microbiology (Reading)*. 2001;147:3345–52. <https://doi.org/10.1099/00221287-147-12-3345>
 38. Lam MMC, Wick RR, Wyres KL, Gorrie CL, Judd LM, Jenney AWJ, et al. Genetic diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICEKp in *Klebsiella pneumoniae* populations. *Microb Genom*. 2018;4:e000196. <https://doi.org/10.1099/mgen.0.000196>
 39. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne *bla*_{KPC-3} mutations during treatment of carbapenem-resistant *Klebsiella pneumoniae* infections. *Antimicrob Agents Chemother*. 2017;61:e02097-16. <https://doi.org/10.1128/AAC.02097-16>
 40. Tooke CL, Hinchliffe P, Bonomo RA, Schofield CJ, Mulholland AJ, Spencer J. Natural variants modify *Klebsiella pneumoniae* carbapenemase (KPC) acyl-enzyme conformational dynamics to extend antibiotic resistance. *J Biol Chem*. 2021;296:100126. <https://doi.org/10.1074/jbc.RA120.016461>
 41. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, et al. Diversity, virulence, and antimicrobial resistance of the KPC-producing *Klebsiella pneumoniae* ST307 clone. *Microb Genom*. 2017;3:e000110. <https://doi.org/10.1099/mgen.0.000110>
 42. Zhang Z, Du W, Wang M, Li Y, Su S, Wu T, et al. Contribution of the colicin receptor CirA to biofilm formation, antibiotic resistance, and pathogenicity of *Salmonella* Enteritidis. *J Basic Microbiol*. 2020;60:72–81. <https://doi.org/10.1002/jobm.201900418>
 43. Wyres KL, Holt KE. *Klebsiella pneumoniae* population genomics and antimicrobial-resistant clones. *Trends Microbiol*. 2016;24:944–56. <https://doi.org/10.1016/j.tim.2016.09.007>
 44. Zheng D, Bergen PJ, Landersdorfer CB, Hirsch EB. Differences in fosfomycin resistance mechanisms between *Pseudomonas aeruginosa* and Enterobacterales. *Antimicrob Agents Chemother*. 2022;66:e0144621. <https://doi.org/10.1128/AAC.01446-21>
 45. Ortiz-Padilla M, Portillo-Calderón I, de Gregorio-Iaria B, Blázquez J, Rodríguez-Baño J, Pascual A, et al. Interplay among different fosfomycin resistance mechanisms in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2021;65:e01911-20. <https://doi.org/10.1128/AAC.01911-20>
 46. Thorpe HA, Booton R, Kallonen T, Gibbon MJ, Couto N, Passet V, et al. A large-scale genomic snapshot of *Klebsiella* spp. isolates in Northern Italy reveals limited transmission between clinical and non-clinical settings. *Nat Microbiol*. 2022;7:2054–67. <https://doi.org/10.1038/s41564-022-01263-0>
 47. Arcari G, Di Lella FM, Bibbolino G, Mengoni F, Beccaccioli M, Antonelli G, et al. A multispecies cluster of VIM-1 carbapenemase-producing Enterobacterales linked by a novel, highly conjugative, and broad-host-range IncA plasmid forebodes the reemergence of VIM-1. *Antimicrob Agents Chemother*. 2020;64:e02435-19. <https://doi.org/10.1128/AAC.02435-19>
 48. Liu J, Wang R, Fang M. Clinical and drug resistance characteristics of *Providencia stuartii* infections in 76 patients. *J Int Med Res*. 2020;48:300060520962296. <https://doi.org/10.1177/0300060520962296>
 49. Molnár S, Flonta MMM, Almaş A, Buzea M, Licker M, Rus M, et al. Dissemination of NDM-1 carbapenemase-producer *Providencia stuartii* strains in Romanian hospitals: a multicentre study. *J Hosp Infect*. 2019;103:165–9. <https://doi.org/10.1016/j.jhin.2019.04.015>
 50. Akbiyik A, Hepçivici Z, Eşer I, Uyar M, Çetin P. The effect of oropharyngeal aspiration before position change on reducing the incidence of ventilator-associated pneumonia. *Eur J Clin Microbiol Infect Dis*. 2021;40:615–22. <https://doi.org/10.1007/s10096-019-03789-4>

Address for correspondence: Alessandra Carattoli, Department of Molecular Medicine, Sapienza University of Rome, Viale di Porta Tiburtina 28, Rome 00185, Italy; email: alessandra.carattoli@uniroma1.it

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Evolution of *Klebsiella pneumoniae* Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy

Appendix 2

Appendix 2 Table 1. Sample type, day of isolate collection, resistance genes, and replicon content identified in *Klebsiella pneumoniae* sequence type 512 genomes analyzed in this study*

Isolate	Sample source	Collection day	β -lactamases	Other acquired resistance genes	Replicon content
6379	RS	1	<i>bla</i> _{KPC-3} , <i>bla</i> _{SHV-12} , <i>bla</i> _{TEM-1A} , <i>bla</i> _{VIM-1}	<i>aac(6')-lb</i> , <i>aac(6')-lb3</i> , <i>aadA1</i> , <i>aph(3')-XV</i> , <i>catB2</i> , <i>dfrA14</i> , <i>mph(A)</i> , Δ <i>qacE</i> , <i>sul1</i>	ColRNAI, IncA, IncFIB(K), IncFII(K), IncFIB(pQil), IncX3
1186B	RS	24	<i>bla</i> _{KPC-31} , <i>bla</i> _{TEM-1A}	<i>aac(6')-lb</i> , <i>aph(3')-la</i> , <i>mph(A)</i>	ColRNAI, IncFIB(K),† IncFII(K),† IncFIB(pQil),† IncX3
1186T	RS	24	<i>bla</i> _{KPC-31} , <i>bla</i> _{TEM-1A}	<i>aac(6')-lb</i> , <i>aph(3')-la</i> , <i>mph(A)</i>	ColRNAI, IncFIB(K),† IncFIB(pQil), IncFII(K), IncX3
6099	RT	51	<i>bla</i> _{KPC-154} , <i>bla</i> _{TEM-1A}	None	IncFIB(K), IncFIB(pQil), IncX3
0296	RT	88	<i>bla</i> _{KPC-3} , <i>bla</i> _{SHV-12} , <i>bla</i> _{TEM-1A} , <i>bla</i> _{VIM-1}	<i>aac(6')-lb</i> , <i>aac(6')-lb3</i> , <i>aadA1</i> , <i>aadA2</i> , <i>aph(3')-la</i> , <i>aph(3')-XV</i> , <i>catB2</i> , <i>catA1</i> , <i>dfrA14</i> , <i>dfrA12</i> , <i>mph(A)</i> , <i>mph(A)</i> , Δ <i>qacE</i> , Δ <i>qacE</i> , <i>sul1</i> , <i>sul1</i>	ColRNAI, IncA, IncFIB(K),‡ IncFII(K),‡ IncFIB(pQil),‡ IncX3

*Virulence and resistance genes were identified by using Kleborate (28, main text) software and replicons were identified by using PlasmidFinder (26, main text). RS, rectal swab sample, RT, respiratory tract sample.

†Replicon integrated in the chromosome.

‡pKpQIL-pKPN fused plasmid.

Appendix 2 Table 2. MICs of antimicrobial drugs used to treat *Escherichia coli* recombinant clones carrying *bla*_{KPC} gene variants KPC-31 and KPC-154 from *Klebsiella pneumoniae* sequence type 512*

Antimicrobial drugs	MIC (mg/L)	
	KPC-31	KPC-154
AUG	≤8	>32
AZT	≤1	>4
CFZ	≤16	>16
CPE	≤0,5	2
CZA	>8	8
ETP	≤0.12	≤0.12
MEM	≤0.12	≤0.12
P/T	≤8	16

*Gene variants from *K. pneumoniae* were cloned into pCR-Blunt II TOPO-NeoR Vector (Thermo Fisher Scientific, <https://www.thermofisher.com>). AUG, amoxicillin/clavulanic acid; AZT, aztreonam; CFZ, cefazolin; CPE, cefepime; CZA, ceftazidime/avibactam; ETP, ertapenem; MEM, meropenem; P/T, piperacillin/tazobactam.